Literature DB >> 9666869

Inhibin A and inhibin B in women with polycystic ovarian syndrome during treatment with FSH to induce mono-ovulation.

R A Anderson1, N P Groome, D T Baird.   

Abstract

OBJECTIVE: Polycystic ovary syndrome (PCOS) is characterized by the presence of numerous small antral follicles arrested at a diameter of less than 10 mm. As development of large antral follicle(s) can be stimulated by the administration of FSH, it has been suggested that the arrest of follicle development is due to a relative lack of or resistance to FSH. We have measured the concentration of FSH and LH and the ovarian hormones oestradiol, inhibin A and B, in relation to the dynamics of follicular development in women with PCOS under basal conditions and during treatment with FSH.
DESIGN: The concentrations of FSH, LH, oestradiol, inhibin A and B were measured in women with PCOS who were untreated (n = 9) or following progesterone-induced menses (10 cycles in six women) and control women on day 3 of a normal cycle (n = 10). Serial measurements of the same hormones were made during induction of ovulation with low dose of exogenous FSH in the women with PCOS who had been treated with progesterone. The dynamics of follicle development were measured by serial pelvic ultrasound examinations during treatment with FSH in PCOS and in the follicular phase of control cycles. PATIENTS: Nine anovulatory untreated women with PCOS were compared with 10 normal women and six women with PCOS undergoing FSH treatment.
RESULTS: The concentrations of inhibin B and LH were higher in both groups of women with PCOS than in normal control women on day 3. In untreated women with PCOS the concentration of inhibin A was also significantly elevated compared to control women (P < 0.01) but not in women pretreated with progesterone. Basal concentrations of oestradiol were also significantly higher in women with PCOS than in the early follicular phase of the normal cycle. There were no significant differences in the concentration of FSH between the groups. Treatment of women with PCOS with low doses of FSH stimulated the development of a single dominant follicle which had an identical rate of growth and secretion of oestradiol and inhibin A to that observed in spontaneous cycles in normal women. In contrast to normal women, the concentration of inhibin B rose 7-fold following FSH treatment and remained elevated until the luteal phase.
CONCLUSIONS: The raised concentrations of inhibin A and B in women with PCOS probably reflects the increased number of small antral follicles characteristically present in that condition. The striking similarity in the dynamics of growth of the dominant follicle and the pattern in concentration of oestradiol and inhibin A in normal women and in women with PCOS treated with modest amounts of FSH, suggests that the arrest of follicle development in PCOS may be due to a relative deficiency of FSH which may in turn be secondary to increased secretion of either or both inhibin forms.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9666869     DOI: 10.1046/j.1365-2265.1998.00442.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  12 in total

1.  Luteal-phase inhibin A and follicular-phase inhibin B levels are not characteristic of patients with an elevated LH-to-FSH ratio.

Authors:  Erik E Hauzman; Péter Fancsovits; Akos Murber; Thomas Rabe; Thomas Strowitzki; Zoltán Papp; János Urbancsek
Journal:  J Assist Reprod Genet       Date:  2006-03       Impact factor: 3.412

Review 2.  Inhibin at 90: from discovery to clinical application, a historical review.

Authors:  Yogeshwar Makanji; Jie Zhu; Rama Mishra; Chris Holmquist; Winifred P S Wong; Neena B Schwartz; Kelly E Mayo; Teresa K Woodruff
Journal:  Endocr Rev       Date:  2014-07-22       Impact factor: 19.871

3.  Hypertension induces gonadal macrophage imbalance, inflammation, lymphangiogenesis, and dysfunction.

Authors:  Shobana Navaneethabalakrishnan; Brooke K Wilcox; Bethany L Goodlett; Malea M Murphy; Brett M Mitchell
Journal:  Clin Sci (Lond)       Date:  2022-06-17       Impact factor: 6.876

4.  Comparison of inhibin B and estradiol responses to intravenous FSH in women with polycystic ovary syndrome and normal women.

Authors:  Marcus A Rosencrantz; Deborah S Wachs; Mickey S Coffler; Pamela J Malcom; Michael Donohue; R Jeffrey Chang
Journal:  Hum Reprod       Date:  2009-10-22       Impact factor: 6.918

Review 5.  Extra- and intra-ovarian factors in polycystic ovary syndrome: impact on oocyte maturation and embryo developmental competence.

Authors:  Jie Qiao; Huai L Feng
Journal:  Hum Reprod Update       Date:  2010-07-16       Impact factor: 15.610

6.  Inhibin secretion in women with the polycystic ovary syndrome before and after treatment with progesterone.

Authors:  Konstantinos Dafopoulos; Christos Venetis; Christina I Messini; Spyros Pournaras; George Anifandis; Antonios Garas; Ioannis E Messinis
Journal:  Reprod Biol Endocrinol       Date:  2011-04-29       Impact factor: 5.211

7.  Inhibin removes the inhibitory effects of activin on steroid enzyme expression and androgen production by normal ovarian thecal cells.

Authors:  J M Young; A S McNeilly
Journal:  J Mol Endocrinol       Date:  2012-01-25       Impact factor: 5.098

8.  The local effects of ovarian diathermy in an ovine model of polycystic ovary syndrome.

Authors:  Fiona Connolly; Michael T Rae; Mairead Butler; Alexander L Klibanov; Vassilis Sboros; Alan S McNeilly; W Colin Duncan
Journal:  PLoS One       Date:  2014-10-24       Impact factor: 3.240

Review 9.  Endocrinology and physiology of pseudocyesis.

Authors:  Juan J Tarín; Carlos Hermenegildo; Miguel A García-Pérez; Antonio Cano
Journal:  Reprod Biol Endocrinol       Date:  2013-05-14       Impact factor: 5.211

10.  Expression and activity of Rac1 is negatively affected in the dehydroepiandrosterone induced polycystic ovary of mouse.

Authors:  Vineet Kumar Maurya; Chadchan Sangappa; Vijay Kumar; Sahil Mahfooz; Archana Singh; Singh Rajender; Rajesh Kumar Jha
Journal:  J Ovarian Res       Date:  2014-03-14       Impact factor: 4.234

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.